DoW Multiple Sclerosis Clinical Trial Award

General Information Document Type: Grants Notice Funding Opportunity Number: HT942526MSRPCTA Funding Opportunity Title: DoW Multiple Sclerosis Clinical Trial Award Opportunity Category: Discretionary Opportunity Category Explanation: Funding Instrument Type: Grant Category of Funding Activity: Science and Technology and other Research and Development Category Explanation: Expected Number of Awards: 3 Assistance Listings: 12.420 -- Military Medical Research and Development Cost Sharing or Matching Requirement: No Version: Synopsis 1 Posted Date: May 05, 2026 Last Updated Date: May 05, 2026 Original Closing Date for Applications: Aug 13, 2026 Current Closing Date for Applications: Aug 13, 2026 Archive Date: Sep 12, 2026 Estimated Total Program Funding: $ 4,000,000 Award Ceiling: $ Award Floor: $ Eligibility Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: Additional Information Agency Name: Defense Health Agency Contracting Activity - DHACA Description: Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level: Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required. Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required. For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted. Link to Additional Information: Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact: eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org CDMRP Help Desk